Marinomed Biotech AG Logo

Marinomed Biotech AG

ISIN: ATMARINOMED6 | Ticker: MARI | LEI: 529900GN3B1EN80XF405
Sector: Health CareSub-Industry: Biotechnology
Country: Austria

About Marinomed Biotech AG

Company Description

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota carrageenan.

Year founded

2006

Served area

Worldwide

Headcount

37

Headquarters

Hovengasse 25, 2100 Korneuburg – Austria

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 23,501,600.00 21,337,000.00 22,286,600.00
Noncurrent Assets N/A 8,105,400.00 8,459,600.00 8,019,000.00
Property Plant And Equipment N/A 6,036,400.00 6,431,700.00 6,203,300.00
Intangible Assets Other Than Goodwill N/A 2,056,800.00 2,007,300.00 1,804,100.00
Other Noncurrent Nonfinancial Assets N/A 12,200.00 20,500.00 11,600.00
Current Assets N/A 15,396,100.00 12,877,500.00 14,267,500.00
Inventories N/A 926,100.00 1,027,400.00 1,562,100.00
Trade And Other Current Receivables N/A 5,263,100.00 6,047,900.00 4,527,400.00
Current Tax Assets Current N/A N/A 0.00 2,800.00
Cash and cash equivalents 12,019,600.00 9,206,900.00 5,802,100.00 8,175,400.00
Equity And Liabilities N/A 23,501,600.00 21,337,000.00 22,286,600.00
Equity 10,866,000.00 5,357,600.00 191,400.00 -4,157,100.00
Issued Capital N/A 1,472,700.00 1,480,200.00 1,506,200.00
Retained Earnings N/A -37,466,300.00 -43,357,600.00 -49,755,300.00
Capital Reserve N/A 41,351,200.00 42,068,800.00 44,092,100.00
Noncurrent Liabilities N/A 12,535,600.00 15,132,000.00 N/A
Other Noncurrent Payables N/A 78,500.00 87,700.00 304,900.00
Longterm Borrowings N/A 12,457,100.00 15,044,300.00 20,182,100.00
Current Liabilities N/A 5,608,400.00 6,013,700.00 N/A
Other Shortterm Provisions N/A 763,000.00 0.00 N/A
Trade And Other Current Payables To Trade Suppliers N/A 1,975,800.00 1,994,900.00 1,153,200.00
Other Current Financial Liabilities N/A 2,512,700.00 3,264,800.00 2,357,900.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 8,124,400.00 11,627,800.00 11,275,900.00
Other Income 1,161,300.00 1,574,600.00 837,600.00
Raw Materials And Consumables Used 5,414,200.00 6,428,300.00 7,283,000.00
Services Expense 3,351,900.00 3,775,200.00 1,852,200.00
Employee Benefits Expense 4,097,900.00 4,461,700.00 4,848,700.00
Depreciation And Amortisation Expense 428,400.00 608,900.00 669,700.00
Other Expense By Nature 1,809,200.00 2,073,100.00 2,373,600.00
Profit Loss From Operating Activities -5,816,000.00 -4,144,700.00 -4,913,600.00
Finance Income 523,000.00 0.00 1,194,400.00
Finance Costs 713,700.00 1,549,500.00 2,671,700.00
Profit Loss Before Tax -6,006,700.00 -5,694,200.00 -6,390,900.00
Income Tax Expense Continuing Operations 3,500.00 197,100.00 6,800.00
Profit (loss) -6,010,200.00 -5,891,300.00 -6,397,700.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -6,010,200.00 -5,891,300.00 -6,397,700.00
Adjustments For Finance Costs N/A 713,700.00 1,549,500.00 2,671,700.00
Adjustments For Decrease Increase In Inventories N/A 828,600.00 101,300.00 534,700.00
Adjustments For Depreciation And Amortisation Expense N/A 428,400.00 608,900.00 669,700.00
Adjustments For Provisions N/A 0.00 763,000.00 0.00
Income Taxes Paid Refund Classified As Operating Activities N/A 3,500.00 197,100.00 6,800.00
Cash Flows From Used In Operating Activities N/A -6,884,900.00 -4,866,300.00 -5,202,900.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A N/A 0.00 20,100.00
Cash Flows From Used In Investing Activities N/A -3,963,500.00 -918,800.00 -207,500.00
Proceeds From Borrowings Classified As Financing Activities N/A 8,000,000.00 1,800,000.00 6,200,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 78,700.00 23,100.00 16,400.00
Cash Flows From Used In Financing Activities N/A 8,005,600.00 2,380,200.00 7,783,600.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 2,200.00 34,600.00 1,400.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -2,812,700.00 -3,404,800.00 2,373,200.00
Cash and cash equivalents 12,019,600.00 9,206,900.00 5,802,100.00 8,175,400.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

ATMARINOMED6

LEI

529900GN3B1EN80XF405

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Vienna Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.